India, Jan. 14 -- Neuren Pharmaceuticals Ltd. (NURPF.OB,NEU.AX) Wednesday said that global net sales of DAYBUE, its prescription drug for Rett syndrome, is expected to touch $700 million in 2028. The biopharmaceutical company said that worldwide net sales benefited from more than 2,000 Rett patients being treated with DAYBUE since its U.S. launch, with 12-month treatment persistency up by 55 percent.
Global net sales also benefitted from the continued gains from the expansion of US customer-facing teams in the second quarter of 2025, the company said in an official statement.
Looking ahead, Neuren Pharma said that the DAYBUE STIX formulation will begin its U.S. launch in the first quarter of 2026, with a full commercial rollout being pla...